NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/05/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization26.96 mln
Float27.26 mln
Earnings Date08/06/2026
Piotroski F-Score
1
/ 9
Very weak
Relative Strength
24
/ 100
Significantly lagging
Debt / Equity
0.17
Very low leverage
ROE
-59.05
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Barinthus Biotherapeutics is a US and UK-based company focused on developing treatments that work with the immune system to address diseases like celiac disease, chronic hepatitis B, cancer, and certain infections. The company has two leading drug candidates currently in clinical trials and works under licensing agreements with Oxford University and the US National Institutes of Health to advance its research. Founded in 2016 and headquartered in Germantown, Maryland, the company was previously known as Vaccitech plc before rebranding in late 2023.
